Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

Catalog #: 349-F4
17 Citations 1 Review Datasheet

Catalog #	Availability	Size / Price	Qty
349-F4-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

All VEGFR3/Flt-4 Proteins and Enzymes

Product Details

Citations (17)

FAQs

Supplemental Products

Reviews (1)

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGFR3/Flt‑4 Fc Chimera at 5 μg/mL (100 μL/well) binds Recombinant Human VEGF-D (Catalog # 622-VD) with an apparent K_d <15 nM.

Source

Mouse myeloma cell line, NS0-derived human VEGFR3/Flt-4 protein

Human Flt-4 (Tyr25-Ile776) & (Ser473-Ile776) Accession # P35916	IEGRDMD	Human IgG₁ (Pro100-Lys330)	6-His tag
N-terminus			C-terminus

Accession #

P35916

N-terminal Sequence
Analysis

Tyr25 & Ser473

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

112 kDa (monomer)

SDS-PAGE

145-150 kDa, 90-95 kDa and 75-80 kDa, reducing conditions

Product Datasheets

349-F4

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

349-F4

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 200 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR3/Flt-4

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt‑1) and VEGFR3 (Flt‑4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt‑4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

References

Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 3

Entrez Gene IDs

2324 (Human); 14257 (Mouse)

Alternate Names

EC 2.7.10; EC 2.7.10.1; FLT4; Flt-4; fms-related tyrosine kinase 4; LMPH1A; PCLFLT41; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; Tyrosine-protein kinase receptor FLT4; vascular endothelial growth factor receptor 3; VEGF R3; VEGFR3; VEGFR-3; VEGFR3Fms-like tyrosine kinase 4

Related Research Areas

Citations for Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression
Authors: Mondal, DK;Xie, C;Buraschi, S;Iozzo, RV;
bioRxiv : the preprint server for biology
Species: N/A
Sample Types: Recombinant Protein
Applications: Bioassay
PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation
Authors: TM Chang, PY Chu, HY Lin, KW Huang, WC Hung, YS Shan, LT Chen, HJ Tsai
Journal of Biomedical Science, 2022-11-06;29(1):92.
Species: Human, Mouse
Sample Types: Transduced Whole Cells
Applications: Bioassay
Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth
Authors: J Zhang, H Li, Q Wu, Y Chen, Y Deng, Z Yang, L Zhang, B Liu
Redox Biol, 2019-02-06;22(0):101116.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Neutralization
Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics
Authors: SB Mamer, S Chen, JC Weddell, A Palasz, A Wittenkell, M Kumar, PI Imoukhuede
Sci Rep, 2017-11-27;7(1):16439.
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance
Differential receptor binding and regulatory mechanisms for the lymphangiogenic growth factors VEGF-C and VEGF-D
Authors: Marc G Achen
J. Biol. Chem., 2016-11-16;0(0):.
Applications: Bioassay
Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
Authors: Terrance G Johns
Sarcoma, 2016-10-16;2016(0):3484673.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis.
Authors: Kyu-Yeon Han, Jin-Hong Chang, Hyun Lee, Dimitri T Azar
Investigative Ophthalmology & Visual Science, 2016-06-01;0(0):1552-5783.
Species: Human
Sample Types: Recombinant Protein
Applications: Enzyme Assay
The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
Authors: Harris, Nicole C, Davydova, Natalia, Roufail, Sally, Paquet-Fifield, Sophie, Paavonen, Karri, Karnezis, Tara, Zhang, You-Fang, Sato, Teruhiko, Rothacker, Julie, Nice, Edouard, Stacker, Steven A, Achen, Marc G
J Biol Chem, 2013-02-12;288(12):8176-86.
Species: Human
Sample Types: Protein
Applications: Bioassay
Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model.
Authors: Tabata T, Petitt M, Fang-Hoover J, Rivera J, Nozawa N, Shiboski S, Inoue N, Pereira L
Am J Pathol, 2012-09-07;181(5):1540-59.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
Authors: Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML
Carcinogenesis, 2009-12-01;30(12):2005-13.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Authors: Mouawad R, Spano JP, Comperat E, Capron F, Khayat D
Eur. J. Cancer, 2009-01-20;45(8):1407-14.
Applications: ELISA Developmet

Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.
Authors: Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, Olsen BR, Alitalo K
Nat. Cell Biol., 2008-04-20;10(5):527-37.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
Authors: Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K
J. Exp. Med., 2007-05-29;204(6):1431-40.
Species: Porcine
Sample Types: Whole Cells
Applications: Bioassay

Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation.
Authors: Red-Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, Maltepe E, Okazaki K, Kochman R, Vo KC, Giudice L, Erlebacher A, McCune JM, Stoddart CA, Fisher SJ
J. Clin. Invest., 2006-09-21;116(10):2643-52.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
Nat. Neurosci., 2006-02-05;9(3):340-8.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
Authors: Lin J, Lalani AS, Harding TC
Cancer Res., 2005-08-01;65(15):6901-9.
Applications: ELISA (Standard)

Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
Authors: Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS
Int. J. Cancer, 2003-05-01;104(5):603-10.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay